Safety and Efficacy of Prasugrel with Endovascular Treatment for Unruptured Cerebral Aneurysm

• DOI: 10.5797/jnet.oa.2017-0047
• Publication Date: 2017-07-04T22:09:50Z
• Authors: Koichi Arimura; Hirotoshi Imamura; Chiaki Sakai; Shoichi Tani; Hidemitsu Adachi; Takayuki Funatsu; Mikiya Beppu; Noriyoshi Takebe; Keita Suzuki; Tomohiro Okuda; Yuichi Matsui; Yasunori Yoshida; Syuhei Kawabata; Nobuyuki Sakai
• Keywords: Thienopyridine

Objective: Recently, dual-antiplatelet therapy (DAPT) including clopidogrel (CLP) with endovascular treatment for unruptured cerebral aneurysm has been widely accepted. However, patients who are poor metabolizers of CLP (CLP-PMs) more frequent in East Asians than Caucasians, and an adequate antiplatelet effect may not be achieved a normal dose such patients. Prasugrel, which is novel thienopyridine drug that less likely to poorly metabolized CLP, used percutaneous coronary intervention, but its efficacy safety neuroendovascular have elucidated. From this point view, the purpose study was elucidate prasugrel aneurysm.